Clinical Trial Update: The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the effect of zoledronic acid on bone loss in prostate cancer patients receiving androgen deprivation therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 4 | Status: COMPLETED